ALRT1057 data

Investigators reported interim results of a Phase I/II single daily dose trial of ALRT1057 oral capsules. As presented at the American Society of Clinical Oncology meeting in Philadelphia, 15 patients with APL received daily doses ranging from 30-230 mg/m 2. Of those, 6 had complete clinical remissions and have remained in remission for 2-18 months.

Of the 15 patients, 4 were newly diagnosed and 11 had relapsed from prior therapy. Of the 6 in remission, 3 were newly diagnosed, 2 had relapsed from complete remissions induced by all-trans retinoic acid, and 1 had relapsed from prior chemotherapy. ...